Table 3.
Demographics and clinical and treatment characteristics for patients with haemophilia B receiving standard half-life vs. extended half-life factor IX replacement products in the United States and Europe
| Characteristic | The United States, N = 22 | Europe, N = 128 | Combined, N = 150 | |||
| SHL group, n = 10 | EHL group, n = 12 | SHL group, n = 104 | EHL group, n = 24 | SHL group, n = 114 | EHL group, n = 36 | |
| Age, mean (SD) (years) | 21.5 (11.2) | 18.5 (8.1) | 28.8 (14.1) | 29.1 (12.9) | 28.1 (14.0) | 25.6 (12.4) |
| Weight, mean (SD) (kg) | 71.8 (33.2) | 64.2 (25.9) | 69.9 (20.1) | 64.8 (18.5) | 69.9 (20.1) | 64.8 (18.5) |
| BMI, mean (SD) (kg/m2) | 26.6 (7.0) | 21.9 (5.4) | 24.1 (5.9) | 23.1 (3.3) | 24.4 (6.0) | 22.7 (4.1) |
| Race/ethnicity, n (%)a | ||||||
| White | 6 (60.0) | 6 (50.0) | 91 (87.5) | 23 (95.8) | 97 (85.1) | 29 (80.6) |
| Black/African American | 3 (30.0) | 2 (16.7) | 0 | 0 | 3 (2.6) | 2 (5.6) |
| Hispanic/Latino | 0 | 4 (33.3) | 1 (1.0) | 0 | 1 (0.9) | 4 (11.1) |
| Otherb | 1 (10.0) | 0 | 12 (11.5) | 1 (4.2) | 13 (11.4) | 1 (2.8) |
| Haemophilia severity, n (%) | ||||||
| Moderate | 3 (30) | 1 (8) | 61 (59) | 17 (71) | 64 (56) | 18 (50) |
| Severe | 7 (70) | 11 (92) | 43 (41) | 7 (29) | 50 (44) | 18 (50) |
| Inhibitor status, n (%) | ||||||
| Never had inhibitors | 10 (100) | 10 (83) | 95 (91) | 24 (100) | 105 (92) | 34 (94) |
| Had inhibitors in the pastc | 0 | 2 (17) | 9 (9) | 0 | 9 (8) | 2 (6) |
| Treatment | ||||||
| Frequency of dose per week, mean (SD) | 2.4 (0.90) | 0.9 (0.36) | 2.1 (0.72) | 1.2 (0.95) | 2.1 (0.74) | 1.1 (0.80) |
| Factor per dose, mean (SD) (IU/kg) | 50.0 (9.40) | 43.8 (10.30) | 41.7 (14.0) | 53.9 (26.2) | 42.5 (13.8) | 50.2 (22.1) |
| Total dose per week, mean (SD) (IU/kg) | 120.0 (32.1) | 39.8 (17.14) | 87.2 (40.49) | 53.7 (27.09) | 90.8 (40.76) | 48.1 (24.28) |
EHL, extended half-life; SHL, standard half-life.
aTotal percentage may not equal 100% because of rounding.
bOther includes Afro-Caribbean, Asian-Indian subcontinent, other Asian, Middle Eastern, and unknown.
cNo patient had inhibitors at baseline.